Compare · BMRA vs NEOG
BMRA vs NEOG
Side-by-side comparison of Biomerica Inc. (BMRA) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.59B, about 241.4x BMRA ($10.7M).
- BMRA has been more active in the news (10 items in the past 4 weeks vs 6 for NEOG).
- NEOG has more recent analyst coverage (6 ratings vs 1 for BMRA).
- Company
- Biomerica Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- $10.7M
- $2.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 10
- 6
- Recent ratings
- 1
- 6
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest BMRA
- SEC Form 3 filed by new insider Qu Xiaoxuan
- Biomerica Reports Fiscal 2026 Year-End Financial Results
- SEC Form 10-K filed by Biomerica Inc.
- Director Gary M. Huff bought $50,000 worth of shares (31,250 units at $1.60), increasing direct ownership by 156% to 51,250 units (SEC Form 4)
- Director Moatazedi David bought $16,000 worth of shares (10,000 units at $1.60), increasing direct ownership by 33% to 40,625 units (SEC Form 4)
- Director Chin Eric bought $10,000 worth of shares (6,250 units at $1.60), increasing direct ownership by 19% to 38,750 units (SEC Form 4)
- Chief Executive Officer Irani Zackary S. bought $50,000 worth of shares (31,250 units at $1.60), increasing direct ownership by 15% to 242,570 units (SEC Form 4)
- Executive Vice Chairman Barbieri Allen bought $32,000 worth of shares (20,000 units at $1.60), increasing direct ownership by 37% to 73,542 units (SEC Form 4)
- Biomerica Announces $2.23 Million Financing
- Biomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Latest NEOG
- Neogen to Host Investor Day on October 7, 2026
- Neogen upgraded by Piper Sandler with a new price target
- SEC Form DEFA14A filed by Neogen Corporation
- SEC Form DEF 14A filed by Neogen Corporation
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,365 units of Restricted Stock Units, decreasing direct ownership by 7% to 29,331 units (SEC Form 4)
- CEO Nassif Mikheal covered exercise/tax liability with 20,397 units of Restricted Stock Units, decreasing direct ownership by 44% to 25,655 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick was granted 8,584 units of Restricted Stock Units, increasing direct ownership by 36% to 32,155 units (SEC Form 4)
- Senior Vice President Ranalli Tamara A. was granted 25,751 shares (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 38,627 shares (SEC Form 4)
- CFO Riggsbee Richard Bryan was granted 51,502 shares (SEC Form 4)